EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN

Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital,...

Full description

Bibliographic Details
Main Authors: Arif Qayyum Khan, Hala Mansoor, Javed Iqbal Raja, Raja Yasser Shahbaz, Samina Fida, Muhammad Siddique
Format: Article
Language:English
Published: The Army Press 2020-12-01
Series:Pakistan Armed Forces Medical Journal
Subjects:
Online Access:https://pafmj.org/index.php/PAFMJ/article/view/3469
id doaj-144eb38e17b145c0b5e936fe0bcf2179
record_format Article
spelling doaj-144eb38e17b145c0b5e936fe0bcf21792021-09-10T05:06:29ZengThe Army PressPakistan Armed Forces Medical Journal0030-96482411-88422020-12-0170618851891doi.org/10.51253/pafmj.v70i6.34693469EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTANArif Qayyum Khan0Hala Mansoor1Javed Iqbal Raja2Raja Yasser Shahbaz3Samina Fida4Muhammad Siddique5Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanCombined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS) PakistanObjective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.https://pafmj.org/index.php/PAFMJ/article/view/3469hepatitis c virus (hcv)svr 12
collection DOAJ
language English
format Article
sources DOAJ
author Arif Qayyum Khan
Hala Mansoor
Javed Iqbal Raja
Raja Yasser Shahbaz
Samina Fida
Muhammad Siddique
spellingShingle Arif Qayyum Khan
Hala Mansoor
Javed Iqbal Raja
Raja Yasser Shahbaz
Samina Fida
Muhammad Siddique
EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
Pakistan Armed Forces Medical Journal
hepatitis c virus (hcv)
svr 12
author_facet Arif Qayyum Khan
Hala Mansoor
Javed Iqbal Raja
Raja Yasser Shahbaz
Samina Fida
Muhammad Siddique
author_sort Arif Qayyum Khan
title EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_short EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_full EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_fullStr EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_full_unstemmed EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_sort efficacy of first available direct-acting antiviral agent in treatment of chronic hepatitis c; results from a single centre in pakistan
publisher The Army Press
series Pakistan Armed Forces Medical Journal
issn 0030-9648
2411-8842
publishDate 2020-12-01
description Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.
topic hepatitis c virus (hcv)
svr 12
url https://pafmj.org/index.php/PAFMJ/article/view/3469
work_keys_str_mv AT arifqayyumkhan efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
AT halamansoor efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
AT javediqbalraja efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
AT rajayassershahbaz efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
AT saminafida efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
AT muhammadsiddique efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
_version_ 1717758577688444928